⌘K
OverviewStock screenerAnalyst actionsCalendar
MarketsInvestorsSign in
StockUnited StatesNasdaqGS

VTRS

Viatris Inc.

Healthcare · Drug Manufacturers - Specialty & Generic

16.50USD

-0.1100 (-0.66%)

DescriptionHistoricalFinancialsRelative ValueResearchNewsDiscussionOptionsPrice Chart ↗Fundamental Chart ↗

Estimates and surprises

Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.

PeriodConsensus EPS90 days agoRevisions up (30d)Revisions down (30d)
Current quarter$0.65▲$0.6533
Next quarter$0.58▼$0.6215
Current year$2.51▲$2.4750
Next year$2.67▼$2.6833

Recent quarters

Beat in 4 of the last 4

QuarterEstimateActualSurprise
2026-06-30$0.6$0.69+0.09 (+15.0%)
2026-03-31$0.5$0.59+0.09 (+17.5%)
2025-12-31$0.53$0.57+0.04 (+7.4%)
2025-09-30$0.62$0.67+0.05 (+8.5%)

Wall Street coverage

49 ratings from 16 firms

Ratings are attributed to the research firm, not to individual analysts. See every ticker.

FirmActionRatingPrice TargetDate
Leerink PartnersInitiatedOutperform$20Sep 9, 2026
Argus ResearchMaintainedBuy$15 $20Sep 8, 2026
BarclaysMaintainedOverweight$17 $22May 19, 2026
JP MorganMaintainedNeutral$17 $18May 8, 2026
Truist SecuritiesMaintainedBuy$18 $20May 8, 2026
BarclaysMaintainedOverweight$15 $17Mar 24, 2026
Piper SandlerMaintainedNeutral$9 $12Jan 28, 2026
Argus ResearchUpgraded from HoldBuy$15Jan 16, 2026
BarclaysInitiatedOverweight$15Dec 9, 2025
Truist SecuritiesInitiatedBuy$15Oct 15, 2025
Goldman SachsInitiatedNeutral$10Jun 6, 2025
JefferiesMaintainedBuy$15 $13Mar 7, 2025
Piper SandlerReiteratedNeutral$14 $10Mar 5, 2025
BarclaysMaintainedUnderweight$12 $9Feb 28, 2025
B of A SecuritiesMaintainedUnderperform$11 $10Feb 28, 2025
Piper SandlerReiteratedNeutral$13 $14Dec 6, 2024
BarclaysMaintainedUnderweight$11 $12Nov 8, 2024
Piper SandlerReiteratedNeutral$11 $13Mar 28, 2024
Piper SandlerMaintainedNeutral$10 $11Nov 22, 2023
B of A SecuritiesDowngraded from NeutralUnderperform$9Oct 23, 2023
BarclaysDowngraded from Equal-WeightUnderweight$11Jun 23, 2023
BarclaysDowngraded from OverweightEqual-Weight$16 $11Apr 25, 2023
BarclaysDowngraded from OverweightEqual-Weight$11Apr 24, 2023
BarclaysMaintainedOverweight$15 $16Feb 28, 2023
BMO CapitalDowngraded from OutperformMarket Perform$16 $14Feb 17, 2023

Analyst Notes

Sign in to write

No analyst notes on VTRS yet.

Analyst Ratings

8 analysts covering

PeriodStrong BuyBuyHoldSellStrong SellConsensus
Current14401Hold2.60
1 mo ago14401Hold2.60
2 mo ago14401Hold2.60
3 mo ago14401Hold2.60
Price target$18.50$12.00 – $23.00
+12.1% to target